Abstract
Cutaneous sarcoidosis is a chronic, inflammatory, granulomatous disorder of unknown etiology that can be recalcitrant to many therapeutic modalities. A number of treatments have been reported to be effective, but none are uniformly successful. Therapy should be tailored to the individual patient and is dependent on the extent of cutaneous involvement and the degree of systemic manifestations. Corticosteroids and antimalarials are the cornerstones of treatment, although cytotoxic agents and numerous anecdotal anti-inflammatory agents have been used. Recently introduced biologics have ushered in a new era of therapeutic options for this potentially serious disorder.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.